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1. Introduction
Glioblastoma is the one of the most malignant brain tumors. The average survival of patients
with glioblastoma is approximately one year, despite aggressive therapeutic efforts. Glioblas‐
toma is associated with peritumoral brain edema. This brain edema is caused by tumor
infiltration into the normal brain and breakdown of the blood brain barrier. Osmotic diuretics,
like glycerol and mannitol, are frequently used to reduce brain edema. The effective duration
of these osmotic diuretics is a few hours, so frequent intravenous infusions are required to
control brain edema in these patients. Steroids are effective for repairing the damaged blood
brain barrier. Therefore, the patients with advanced glioblastoma need to be administered
long-term osmotic diuretics and steroids. Both of these types of agents have various side effects.
Saireito is a commercially available Chinese herbal medicine that combines Syousaikotou and
Goreisan, both of them are also commercially available Chinese herbal medicine. Syousaikotou
has steroid-like effects and Goreisan has a diuretic effect. There have been some clinical reports
of a beneficial effect of Saireito or Goreisan for chronic subdural hematoma and other condi‐
tions. However, there have been no reports about the clinical effects of Saireito in patients with
malignant brain tumors. We evaluated the clinical effects of Saireito for patients with advanced
stage glioblastoma.
2. Patients and methods
Saireito was administered to eight patients diagnosed with advanced stage glioblastoma. The
tumor locations were cerebral in seven cases and in the pons in one case. There were four males
and four females. The age of the patients ranged from 38 to 86 years old. Seven patients
underwent tumor resection and were pathologically diagnosed with glioblastoma. One patient
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did not receive surgery because of the high age, so glioblastoma was diagnosed clinically. The
seven patients who received surgery were treated with postoperative radiation and chemo‐
therapy. Five patients underwent repeat surgery and additional radiation therapy for recur‐
rence. All patients received temozolomide chemotherapy and interferon immunotherapy
wherever possible. Saireito (2.7 g) was given three times a day for all patients with advanced
stage disease. Saireito was given through a nasogastric tube for the patients who could not
take the medication orally.
3. Representative case report
A 74-year-old male presenting with memory disturbance and right hemiparesis was diagnosed
to have a left frontal brain tumor using brain magnetic resonance imaging (MRI). The tumor
was surgically removed, and the pathological diagnosis was glioblastoma. He received
postsurgical radiation therapy and concomitant oral chemotherapy with temozolomide. After
these initial therapies, maintenance chemotherapy with temozolomide and intravenous
infusion of interferon were continued. His consciousness deteriorated one year after the initial
therapy. He could not take medication orally, so we started parenteral nutrition using a
nasogastric tube. Brain MRI showed an increase in bilateral frontal edema (Fig. 1). Therefore,
we first administered intravenous glyceol; however, we considered permanent intravenous
administration of glyceol to be difficult. Therefore, we started parenteral Saireito administra‐
tion and terminated the intravenous glyceol treatment. The patient’s condition remained
unchanged, so he discharged, and the nasogastric parenteral nutrition and Saireito adminis‐
tration were continued at his home. He underwent repeat short-term hospitalization for
scheduled chemotherapy and intravenous infusion of interferon (Fig. 2)
Figure 1. Fluid attenuated inversion recovery (FLAIR) MRI image
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Figure 2. Gadolinium-DTPA enhanced T1 weighted image and FLAIR image
Figure 3. Gadolinium-DTPA enhanced T1 weighted image and FLAIR image
About one year after the initiation of Saireito, he developed intestinal bleeding and pleural
effusion. Chest and abdominal computed tomography showed multiple tumors. The paren‐
teral nutrition and medication were terminated. He died because of intestinal bleeding two
years after the initial diagnosis of the brain tumor. The final brain MRI showed a stable brain
tumor and perifocal edema (Fig. 3). The tumor diameter on fluid attenuated inversion recovery
(FLAIR) and gadolinium-diethylene triamine pentaacetic acid (DTPA)-enhanced T1-weighted
MRI (GdT1) was plotted in Figure 4. Before the administration of Saireito, the tumor diameter
in FLAIR was continuously increasing. After the initiation of Saireito administration, the tumor
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diameter in FLAIR became stable, although the tumor diameter in GdT1 continuously
increased. Because of his poor renal function, GdT1 MRI was not performed during the early
stage of follow-up.
Figure 4. Temporal change of Tumor diameter in MRI
4. Results
All eight patients died. The survival time of the patients ranged from four to 35 months, with
a mean of 18.4 months, and a median of 22 months. Saireito was given to all of the patients
until almost the end of the life. The direct causes of death were tumor growth in four patients,
central nervous system failure without tumor growth in one patient, and another malignancy,
pneumonia and a hyperglycemic coma in one patient each. The continuous glycerol infusion
was stopped after Saireito administration in all patients. The steroid administration was
stopped for two patients and reduced for two patients after Saireito administration. The
interval from the initiation of Saireito to death ranged from one to 12 months, with a mean of
5.9 months and a median of three months. The Karnofsky performance status (KPS) was used
to assess the patient’s general condition [1]. The KPS of all patients who received Saireito was
less than 50 at the time of initiation. The radiation therapy oncology group recursive parti‐
tioning analysis (RTOG RPA) was used as an index of the prognosis [2]. The RTOG RPA of all
patients who received Saireito was Stage VI. The mean prognosis of RTOG RPA Stage VI is
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five months. Therefore, a prolongation of survival was observed for four of the eight patients.
For the patients who took Saireito for less than four months, no prolongation of survival was
observed. On the other hand, prolonged survival was observed in the patients who took
Saireito for more than six months. No significant side effects of Saireito were observed. The
administration of Saireito is covered by the Japanese health insurance system, and the cost of
Saireito is less than 400 Japanese yen per day.
Age Sex onset to death Saireito Intake Intake to death Cause of death
75 M 24 12 13 Intestinal bleeding
68 F 35 4 4 neural without tumor
86 M 4 2 2 hyperglycemic coma
62 F 4 1 1 Brain Tumor
59 M 20 2 2 Brain Tumor
58 M 31 8 8 Pneumonia
38 F 11 11 11 Brain Tumor
38 F 20 7 8 Brain Tumor
Mean 19.7 5.9 6.1
Median 22 3 3
Table 1. Summary of the patients
5. Discussion
Saireito is a mixture of Syousaikotou and Goreisan. Syousaikotou has mild steroid-like effects.
In animal studies, Syousaikotou increased the secretion of corticotrophin-releasing hormone
and adrenocorticotropic hormone (ACTH), resulting in an increased cortisol concentration [3]
[4]. Cortisol is effective for decreasing inflammation and brain edema. Long-term administra‐
tion of Saireito does not have the typical side effects of conventional steroids. Saireito and
Goreisan have diuretic effects by controlling the aquaporin function at the cell membrane [5].
Long-term glycerol infusion is associated with some side effects, such as electrolyte imbalance.
However, these side effects have been reported to be rare for Saireito.
There have been some clinical reports about the effective applications of Saireito and Goreisan
for cerebral edema, chronic subdural hematoma and edema at the extremities [6, 7]. However,
the clinical application of Saireito for malignant brain tumors has not been reported previously.
The clinical effects should be confirmed by a randomized controlled study. However, the low
cost and apparently rare side effects appear to be major advantages of this Chinese herbal
medicine.




Saireito was found to be both safe and effective for patients with advanced stage glioblastoma.
Some patients could stop taking glycerol and steroids. Among the eight patients evaluated in
the study, death due to tumor growth was observed in four patients. A prolongation of survival
was observed in four of the eight patients. This Chinese herbal medicine appears to be effective,
and is associated with both a low cost and rare side effects, thereby warranting further studies
in a larger number of patients.
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